Dr Asma Patel, Vice President of Integrated Services for Early Development at Quotient Sciences, reflects on the biggest barriers to rare disease drug development and how companies can overcome these. Despite improvements in regulatory support and commercial rewards, difficulties remain for drug developers in bringing rare disease drugs to market. There are four main barriers […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!